Cannabinoid Program Launches for Neurodegenerative Diseases

An illustration shows different forms of administering cannabis.

InMed Pharmaceuticals will launch a new program – the INM-900 series – that will investigate the therapeutic potential of its cannabinoid analogs in neurodegenerative diseases, including Parkinson’s, the company announced in a press release.

Cannabinoids, also called phytocannabinoids, are the active chemicals that give the cannabis plant its medical and recreational properties and are known to have neuroprotective effects.

They act on the endocannabinoid system, a complex modulatory network involved in brain development, memory, movement control, hormone production, and immune reactions, which has been shown to be altered in Parkinson’s patients.

InMed’s cannabinoid analogs are new compounds that have been tweaked slightly and carry a different molecular architecture than the original cannabinoids in the cannabis plant. While natural cannabinoids isolated from the plant are not patentable, the new analogs can be. Moreover, the cannabinoid analogs have been developed to address disease-specific features.

Recommended Reading

This is an image of various medical marijuana containers that accompanies a story about cannabinoids' effect on motor symptoms of Parkinson's disease in zebrafish.

Cannabinoid Mixtures Ease Parkinson’s Motor Symptoms in Zebrafish

According to InMed’s press release, two cannabinoid analogs have shown promising results for neurodegenerative diseases, specifically, in promoting the growth of neurites, cell body extensions that nerve cells normally use to communicate with each other.

“Our early studies are showing promising neuroprotective effects as well as neurite outgrowth, signifying the potential to enhance neuronal function that may be important in the treatment of neurodegenerative diseases,” said Eric Hsu, PhD, senior vice president of preclinical Research & Development at InMed.

The company will be conducting studies in in vivo models of neurodegenerative diseases.

Our early studies are showing promising neuroprotective effects as well as neurite outgrowth, signifying the potential to enhance neuronal function that may be important in the treatment of neurodegenerative diseases.

“We are pleased that our efforts have led to the identification of two cannabinoid analog candidates to advance to in vivo studies,” Hsu said.

The first preclinical efficacy results are expected by June 2023. The research will be conducted in collaboration with Ujendra Kumar, PhD, professor of Pharmaceuticals Sciences at the University of British Columbia (UBC), Vancouver, Canada.

The project, for which InMed serves as the named industry partner, was awarded an alliance grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) and is titled, “Pharmacological characterization of phytocannabinoids and the endocannabinoid system.”

“Our team will continue this important research in neurodegenerative diseases under the NSERC Alliance grant,” Hsu said.

The post Cannabinoid Program Launches for Neurodegenerative Diseases appeared first on Parkinson's News Today.

https://parkinsonsnewstoday.com/news/new-program-will-explore-cannabinoid-parkinsons-treatment/

Parkinsons News Today

Categories

0 Comments

Submit a Comment

Parkinsons, Odd behaviour and Medications

Parkinsons, Odd behaviour and Medications

Do you have a friend or loved one with Parkinsons ? You reckon that would be bad enough ? Is their behaviour a bit (or a lot or even dangerously) out of character? It may be the drugs they are taking and not their real self or the disease!Please read ALL of this post...

Introduction and Excuse me!

Introduction and Excuse me!

Pardon me, while I get this social media enterprise working. It has taken me 12 months to get this far with this editorial labyrinth. My former pre Parkinson’s self would have had this whipped up in a week or two, reality changes ability, however I won’t let it kill...

They Call me Shuffles

They Call me Shuffles

    A diagnosis with Parkinson's changes a lot of things: Motor function, non-motor functions, but maybe even more powerful is the changes in social interactions. I personally don't mind being called "Shuffles" now, I did at first (8 or so years ago I think), I...